Characterization of a mutation in the reduced folate carrier in a transport defective L1210 murine leukemia cell line

K. E. Brigle, M. J. Spinella, E. E. Sierra, I. David Goldman

Research output: Contribution to journalArticle

101 Citations (Scopus)

Abstract

This laboratory previously described an L1210 leukemia cell line (MTX(r)A) selected for resistance to methotrexate by virtue of impaired transport due to a functional defect in the translocation process. We now report on the sequence analysis of cDNAs encoding the reduced folate carrier from this line and identify a single mutation that results in the substitution of a proline for an alanine in a highly conserved transmembrane region of the protein. Transfection of the parental reduced folate carrier into MTX(r)A cells resulted in a cell line which exhibited a complete restoration of methotrexate uptake and an enhanced sensitivity to methotrexate. Northern analysis and specific [3H]MTX cell surface binding indicated that expression of the reduced folate carrier was elevated ~5-fold in the transfectant compared to parental and MTX(r)A cells. The MTX influx properties of the transfectant cell line were identical to those of the well characterized reduced folate carrier from parental L1210 cells in terms of: 1) patterns of sensitivity to competing folates, 2) sensitivity to the organic anion sulfobromophthalein, 3) lack of energy dependence, and 4) capacity for trans- stimulation. We also provide new data which suggests that the nucleotide sequence 5' of the predicted ATG initiation codon may encode additional protein information in the form of a leader sequence. Finally, we demonstrate that the MTX(r)A line has both the mutant and the parental reduced folate carrier alleles but that expression appears to be restricted to the mutant allele. Thus, the methotrexate transport phenotype and resultant drug resistance in this cell line result from genetic/regulatory events at both alleles.

Original languageEnglish (US)
Pages (from-to)22974-22979
Number of pages6
JournalJournal of Biological Chemistry
Volume270
Issue number39
DOIs
StatePublished - 1995
Externally publishedYes

Fingerprint

Reduced Folate Carrier Protein
Leukemia L1210
Methotrexate
Cells
Cell Line
Mutation
Alleles
Sulfobromophthalein
Initiator Codon
Folic Acid
Drug Resistance
Proline
Alanine
Restoration
Anions
Transfection
Sequence Analysis
Proteins
Substitution reactions
Nucleotides

ASJC Scopus subject areas

  • Biochemistry

Cite this

Characterization of a mutation in the reduced folate carrier in a transport defective L1210 murine leukemia cell line. / Brigle, K. E.; Spinella, M. J.; Sierra, E. E.; Goldman, I. David.

In: Journal of Biological Chemistry, Vol. 270, No. 39, 1995, p. 22974-22979.

Research output: Contribution to journalArticle

@article{72bfe34ff9104565abd808c4591d3292,
title = "Characterization of a mutation in the reduced folate carrier in a transport defective L1210 murine leukemia cell line",
abstract = "This laboratory previously described an L1210 leukemia cell line (MTX(r)A) selected for resistance to methotrexate by virtue of impaired transport due to a functional defect in the translocation process. We now report on the sequence analysis of cDNAs encoding the reduced folate carrier from this line and identify a single mutation that results in the substitution of a proline for an alanine in a highly conserved transmembrane region of the protein. Transfection of the parental reduced folate carrier into MTX(r)A cells resulted in a cell line which exhibited a complete restoration of methotrexate uptake and an enhanced sensitivity to methotrexate. Northern analysis and specific [3H]MTX cell surface binding indicated that expression of the reduced folate carrier was elevated ~5-fold in the transfectant compared to parental and MTX(r)A cells. The MTX influx properties of the transfectant cell line were identical to those of the well characterized reduced folate carrier from parental L1210 cells in terms of: 1) patterns of sensitivity to competing folates, 2) sensitivity to the organic anion sulfobromophthalein, 3) lack of energy dependence, and 4) capacity for trans- stimulation. We also provide new data which suggests that the nucleotide sequence 5' of the predicted ATG initiation codon may encode additional protein information in the form of a leader sequence. Finally, we demonstrate that the MTX(r)A line has both the mutant and the parental reduced folate carrier alleles but that expression appears to be restricted to the mutant allele. Thus, the methotrexate transport phenotype and resultant drug resistance in this cell line result from genetic/regulatory events at both alleles.",
author = "Brigle, {K. E.} and Spinella, {M. J.} and Sierra, {E. E.} and Goldman, {I. David}",
year = "1995",
doi = "10.1074/jbc.270.39.22974",
language = "English (US)",
volume = "270",
pages = "22974--22979",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "39",

}

TY - JOUR

T1 - Characterization of a mutation in the reduced folate carrier in a transport defective L1210 murine leukemia cell line

AU - Brigle, K. E.

AU - Spinella, M. J.

AU - Sierra, E. E.

AU - Goldman, I. David

PY - 1995

Y1 - 1995

N2 - This laboratory previously described an L1210 leukemia cell line (MTX(r)A) selected for resistance to methotrexate by virtue of impaired transport due to a functional defect in the translocation process. We now report on the sequence analysis of cDNAs encoding the reduced folate carrier from this line and identify a single mutation that results in the substitution of a proline for an alanine in a highly conserved transmembrane region of the protein. Transfection of the parental reduced folate carrier into MTX(r)A cells resulted in a cell line which exhibited a complete restoration of methotrexate uptake and an enhanced sensitivity to methotrexate. Northern analysis and specific [3H]MTX cell surface binding indicated that expression of the reduced folate carrier was elevated ~5-fold in the transfectant compared to parental and MTX(r)A cells. The MTX influx properties of the transfectant cell line were identical to those of the well characterized reduced folate carrier from parental L1210 cells in terms of: 1) patterns of sensitivity to competing folates, 2) sensitivity to the organic anion sulfobromophthalein, 3) lack of energy dependence, and 4) capacity for trans- stimulation. We also provide new data which suggests that the nucleotide sequence 5' of the predicted ATG initiation codon may encode additional protein information in the form of a leader sequence. Finally, we demonstrate that the MTX(r)A line has both the mutant and the parental reduced folate carrier alleles but that expression appears to be restricted to the mutant allele. Thus, the methotrexate transport phenotype and resultant drug resistance in this cell line result from genetic/regulatory events at both alleles.

AB - This laboratory previously described an L1210 leukemia cell line (MTX(r)A) selected for resistance to methotrexate by virtue of impaired transport due to a functional defect in the translocation process. We now report on the sequence analysis of cDNAs encoding the reduced folate carrier from this line and identify a single mutation that results in the substitution of a proline for an alanine in a highly conserved transmembrane region of the protein. Transfection of the parental reduced folate carrier into MTX(r)A cells resulted in a cell line which exhibited a complete restoration of methotrexate uptake and an enhanced sensitivity to methotrexate. Northern analysis and specific [3H]MTX cell surface binding indicated that expression of the reduced folate carrier was elevated ~5-fold in the transfectant compared to parental and MTX(r)A cells. The MTX influx properties of the transfectant cell line were identical to those of the well characterized reduced folate carrier from parental L1210 cells in terms of: 1) patterns of sensitivity to competing folates, 2) sensitivity to the organic anion sulfobromophthalein, 3) lack of energy dependence, and 4) capacity for trans- stimulation. We also provide new data which suggests that the nucleotide sequence 5' of the predicted ATG initiation codon may encode additional protein information in the form of a leader sequence. Finally, we demonstrate that the MTX(r)A line has both the mutant and the parental reduced folate carrier alleles but that expression appears to be restricted to the mutant allele. Thus, the methotrexate transport phenotype and resultant drug resistance in this cell line result from genetic/regulatory events at both alleles.

UR - http://www.scopus.com/inward/record.url?scp=0029151314&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029151314&partnerID=8YFLogxK

U2 - 10.1074/jbc.270.39.22974

DO - 10.1074/jbc.270.39.22974

M3 - Article

VL - 270

SP - 22974

EP - 22979

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 39

ER -